FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947660016> ?p ?o ?g. }

• W2947660016 abstract "e13575 Background: Hyperprogressive disease (HPD) has been described in solid tumor patients treated with immune checkpoint inhibitors (ICI). HPD is defined as a ≥2-fold increase in tumor growth rate (TGR) following initiation of ICI. HPD has not been explored in patients with high grade gliomas (HGG) on ICI or standard cytotoxic regimens. In advanced cancer patients receiving ICI, MDM2/4 amplification or EGFR alterations, both found in HGG, correlated with HPD. We compared the rate of HPD in recurrent HGG patients receiving ICIs to those treated with non-immunotherapy agents. Methods: Patients with HGG on ICIs for 1st or 2nd recurrence were compared to a control group receiving other therapies at 1st recurrence. Patients with prior or concurrent bevacizumab or anti-VEGFR were excluded due to pseudoresponse and decreased enhancement with these drugs. HPD was calculated by comparing TGR immediately before and after treatment. Results: 49 patients met inclusion criteria (27 ICI, 25 control). 25/27 patients treated with ICIs and 20/22 patients in the control group had complete imaging and were eligible for analysis. In the ICI group, 60% were men (15/25) and 88% (22/25) had a diagnosis of GBM. 68% were treated at first progression (17/25). Controls were 80% male (16/20) and all had a diagnosis of GBM. 30% (6/20) were 65 years or older at diagnosis in the control group compared to 28% (7/25) in the ICI group. In total, 7/25 patients met criteria for HPD in the ICI group (28%) compared to 4/20 patients in the control group (20%). 10/25 patients (5/7 with HPD) in the ICI group and 8/20 patients (2/4 with HPD) in the control group had next generation sequencing of their tumors. EGFR alterations and MDM2/4 amplifications were not associated with HPD whereas PTEN mutations were more common in the HPD group (71% HPD vs. 33.3% no HPD). Conclusions: HPD is observed in patients with HGG treated with ICI at comparable rates to those with other cancers, but was also observed in 20% of patients receiving other therapies. While the numbers are small, PTEN mutations may be associated with HPD in patients with HGG. In contrast to other solid tumors, EGFR alterations and MDM2/4 amplifications were not associated with HPD in HGG." @default.
• W2947660016 created "2019-06-07" @default.
• W2947660016 creator A5015328297 @default.
• W2947660016 creator A5030819228 @default.
• W2947660016 creator A5035431816 @default.
• W2947660016 creator A5050534702 @default.
• W2947660016 creator A5057541817 @default.
• W2947660016 creator A5076256448 @default.
• W2947660016 creator A5078574890 @default.
• W2947660016 creator A5080062627 @default.
• W2947660016 creator A5087754052 @default.
• W2947660016 date "2019-05-20" @default.
• W2947660016 modified "2023-09-30" @default.
• W2947660016 title "Hyperprogressive disease in patients with recurrent high grade gliomas treated with immune checkpoint inhibitors or other therapies." @default.
• W2947660016 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e13575" @default.
• W2947660016 hasPublicationYear "2019" @default.
• W2947660016 type Work @default.
• W2947660016 sameAs 2947660016 @default.
• W2947660016 citedByCount "0" @default.
• W2947660016 crossrefType "journal-article" @default.
• W2947660016 hasAuthorship W2947660016A5015328297 @default.
• W2947660016 hasAuthorship W2947660016A5030819228 @default.
• W2947660016 hasAuthorship W2947660016A5035431816 @default.
• W2947660016 hasAuthorship W2947660016A5050534702 @default.
• W2947660016 hasAuthorship W2947660016A5057541817 @default.
• W2947660016 hasAuthorship W2947660016A5076256448 @default.
• W2947660016 hasAuthorship W2947660016A5078574890 @default.
• W2947660016 hasAuthorship W2947660016A5080062627 @default.
• W2947660016 hasAuthorship W2947660016A5087754052 @default.
• W2947660016 hasConcept C126322002 @default.
• W2947660016 hasConcept C143998085 @default.
• W2947660016 hasConcept C203014093 @default.
• W2947660016 hasConcept C2777701055 @default.
• W2947660016 hasConcept C2778227246 @default.
• W2947660016 hasConcept C2779134260 @default.
• W2947660016 hasConcept C2780057760 @default.
• W2947660016 hasConcept C2780851360 @default.
• W2947660016 hasConcept C502942594 @default.
• W2947660016 hasConcept C71924100 @default.
• W2947660016 hasConcept C8891405 @default.
• W2947660016 hasConceptScore W2947660016C126322002 @default.
• W2947660016 hasConceptScore W2947660016C143998085 @default.
• W2947660016 hasConceptScore W2947660016C203014093 @default.
• W2947660016 hasConceptScore W2947660016C2777701055 @default.
• W2947660016 hasConceptScore W2947660016C2778227246 @default.
• W2947660016 hasConceptScore W2947660016C2779134260 @default.
• W2947660016 hasConceptScore W2947660016C2780057760 @default.
• W2947660016 hasConceptScore W2947660016C2780851360 @default.
• W2947660016 hasConceptScore W2947660016C502942594 @default.
• W2947660016 hasConceptScore W2947660016C71924100 @default.
• W2947660016 hasConceptScore W2947660016C8891405 @default.
• W2947660016 hasLocation W29476600161 @default.
• W2947660016 hasOpenAccess W2947660016 @default.
• W2947660016 hasPrimaryLocation W29476600161 @default.
• W2947660016 hasRelatedWork W2161637607 @default.
• W2947660016 hasRelatedWork W2528583885 @default.
• W2947660016 hasRelatedWork W2553051584 @default.
• W2947660016 hasRelatedWork W2605513047 @default.
• W2947660016 hasRelatedWork W2735939614 @default.
• W2947660016 hasRelatedWork W2769782763 @default.
• W2947660016 hasRelatedWork W2793938337 @default.
• W2947660016 hasRelatedWork W2797220830 @default.
• W2947660016 hasRelatedWork W287605918 @default.
• W2947660016 hasRelatedWork W2885063772 @default.
• W2947660016 hasRelatedWork W2889707629 @default.
• W2947660016 hasRelatedWork W2898362925 @default.
• W2947660016 hasRelatedWork W2940168172 @default.
• W2947660016 hasRelatedWork W2972357250 @default.
• W2947660016 hasRelatedWork W2972875473 @default.
• W2947660016 hasRelatedWork W3005153390 @default.
• W2947660016 hasRelatedWork W3013766663 @default.
• W2947660016 hasRelatedWork W3088541063 @default.
• W2947660016 hasRelatedWork W3113016898 @default.
• W2947660016 hasRelatedWork W2856797897 @default.
• W2947660016 isParatext "false" @default.
• W2947660016 isRetracted "false" @default.
• W2947660016 magId "2947660016" @default.
• W2947660016 workType "article" @default.